SCHEMBL17882157

SCHEMBL17882157

CON(Cc1ccc(F)cc1)C(=O)C(C)(C)C(C)(F)F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 2/20 0.48
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ GAA P10253 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA7 P43166 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CA14 Q9ULX7 1/20 0.36
▸ NSD2 O96028 1/20 0.35
▸ YAP1 P46937 1/20 0.35
▸ TEAD4 Q15561 1/20 0.35
▸ TEAD2 Q15562 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19448803 0.87 RIPK1 (0.44) RIPK1MEN1KMT2ACA12CA9
SCHEMBL17882186 0.85 RIPK1 (0.51) RIPK1KDM4E
SCHEMBL19448784 0.82 RIPK1 (0.67) RIPK1KDM4E
SCHEMBL17882187 0.81 RIPK1 (0.49) RIPK1KDM4E
SCHEMBL17882168 0.81 RIPK1 (0.52) RIPK1TAS2R14KDM4E
SCHEMBL17882162 0.80 RIPK1 (0.68) RIPK1MEN1KMT2AHPGDTDP1
SCHEMBL17882169 0.75 RIPK1 (0.35) RIPK1
SCHEMBL17882159 0.75 RIPK1 (0.56) RIPK1
SCHEMBL23803521 0.71 RIPK1 (0.68) RIPK1MEN1KMT2AHPGDTDP1
SCHEMBL3682001 0.70 TDP1 (0.39) RIPK1TDP1TAS2R14CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090307-B2 Treating male senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2021-08-17 — — US disclosed
US-10682319-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-06-16 — — US disclosed
US-20200046714-A1 Treating Male Senescence NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2020-02-13 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-9974762-B2 Necrosis inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2018-05-22 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
US-20170290790-A1 Necrosis Inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2017-10-12 — — US disclosed
WO-2016101885-A1 NECROSIS INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2016-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10682319-B2 Necrosis inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885MEN1 3176/4885KMT2A 4194/4885
US-11090307-B2 Treating male senescence RIPK3, RIPK1, MLKL RIPK1 2/4885MEN1 1003/4885KMT2A 2508/4885
US-20200046714-A1 Treating Male Senescence RIPK3, RIPK1, MLKL RIPK1 2/4885MEN1 1003/4885KMT2A 2508/4885
US-20170290790-A1 Necrosis Inhibitors RIPK3, RIPK1, RIPK4 RIPK1 2/4885MEN1 3275/4885KMT2A 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback